Global Plasma Solutions Settles Charges Over Unsubstantiated Air Purifier Pathogen Claims

Global Plasma Solutions, a manufacturer of needle-point bipolar ionization air purification systems, agreed to settle federal charges that its marketing claims — specifically that its technology neutralized COVID-19, bacteria, mold, and other airborne pathogens — were not supported by the scientific evidence it cited or possessed.DOCUMENTED The company's systems were installed in buildings across the country, including schools, offices, healthcare facilities, and transportation infrastructure, in large part because of health and safety claims made during and after the early phase of the COVID-19 pandemic.

Bipolar ionization, the underlying technology in GPS's products, generates charged ions that are introduced into building air systems with the goal of neutralizing pollutants, pathogens, and allergens. The technology had existed in commercial applications before the pandemic, but it experienced a significant surge in interest as building operators sought to improve indoor air quality in response to concerns about airborne COVID-19 transmission.DOCUMENTED Global Plasma Solutions positioned itself at the center of that market with claims about its technology's efficacy that regulators determined were not adequately substantiated.

The Claims and Their Scientific Basis

GPS's marketing materials, distributed to building owners, facilities managers, school administrators, and HVAC contractors, stated that its ionization technology had been demonstrated to reduce concentrations of pathogens including SARS-CoV-2, influenza viruses, bacteria, and mold spores in building air systems.DOCUMENTED The company cited studies and test results in support of these claims. Regulators found, however, that the cited evidence did not meet the standard of competent and reliable scientific evidence required before making health-related efficacy claims — because the studies were conducted under laboratory conditions that did not represent real-world building environments, or used methodologies that did not demonstrate the claimed effect under conditions that would pertain in actual installations.

The gap between laboratory performance under controlled conditions and real-world performance in installed building systems is a recurring evidentiary challenge for air purification technology claims.REVIEWED Conditions in actual buildings — air volume, HVAC configuration, occupancy patterns, pathogen concentrations — differ substantially from the chamber-based test environments where many pathogen reduction studies are conducted. Marketing that translates laboratory results directly into building performance claims without acknowledging this gap can mislead purchasers about what to expect from installed systems.

The Market Context: COVID-Era Indoor Air Quality Claims

The pandemic created an exceptionally receptive market for indoor air quality products. Building operators faced pressure from occupants, regulators, and insurers to demonstrate that their facilities were safe for occupancy, and many were willing to invest substantially in technologies that promised to reduce pathogen transmission risk.REVIEWED This environment created conditions for marketing claims to run ahead of the evidence base — particularly for technologies that had some scientific theoretical basis but lacked the rigorous, peer-reviewed, real-world efficacy studies that would be required to substantiate the specific claims being made in sales and marketing materials.

Global Plasma Solutions was not the only air purification company to face enforcement scrutiny during this period, but it was among the largest and most widely deployed, making its case significant for the facilities management and HVAC industries that had installed its systems at substantial cost based on the efficacy representations at issue.DOCUMENTED

Settlement Terms

The resolution required Global Plasma Solutions to possess competent and reliable scientific evidence before making any claim about the efficacy of its products in reducing, neutralizing, or eliminating pathogens, allergens, or other air pollutants in real-world environments.DOCUMENTED The company was prohibited from representing that its technology had been proven effective by studies that did not meet this evidentiary standard, and was required to correct existing marketing materials that contained the claims at issue.

The settlement also addressed the company's responsibilities to customers who had purchased and installed systems based on the challenged claims. The order did not require the company to repurchase installed equipment, but it did establish requirements around how the company could continue to characterize its technology's performance going forward.DOCUMENTED

Guidance for Facilities Decision-Makers

For building operators, schools, and facilities managers considering air purification investments, the GPS case offers a clear evidentiary framework: before purchasing any system on the basis of pathogen reduction claims, request the underlying studies, verify that those studies were conducted in environments comparable to the intended installation, and consult with an independent industrial hygienist or environmental engineer rather than relying solely on manufacturer-provided materials.REVIEWED

The American Society of Heating, Refrigerating and Air-Conditioning Engineers and the Centers for Disease Control and Prevention have each published guidance on evidence-based approaches to indoor air quality improvement that do not rely on the marketing claims of technology vendors. These provide a neutral framework for evaluating technology claims independent of manufacturer advocacy.

What Facilities Managers Should Know Going Forward

The resolution of the Global Plasma Solutions case has practical implications for building operators who installed GPS systems based on the efficacy claims at issue. The settlement did not establish that the technology is ineffective — it established that the claims made in marketing exceeded what the available evidence could support at the time those claims were made. Building operators who want to evaluate the actual performance of their installed systems should consult independent industrial hygienists, review the growing body of peer-reviewed research on bipolar ionization conducted after the pandemic urgency of initial purchasing decisions has passed, and apply the same evidence standard to any future air quality investment that regulators have now required GPS to apply to its own claims going forward.

The scientific community's assessment of bipolar ionization technology continued to evolve after the GPS settlement, with peer-reviewed studies examining real-world installations producing more nuanced findings than early pandemic-era research suggested. Building operators making decisions about indoor air quality investments should draw on this evolving literature rather than on marketing claims from technology vendors who have a financial stake in particular conclusions. The GPS case established, at minimum, that marketing claims must track the actual state of the scientific evidence at the time they are made — and that the pace of commercial marketing cannot run ahead of the pace of peer-reviewed research without crossing into territory regulators will treat as deceptive.

Have documents relevant to this story? Reach us through our tips channel.